Jump to content

Home

Chobanian & Avedisian School of Medicine/CCE

Open menu
Cart
  • Login
  • Register

Bookmark/Search this post

  • Facebook logo Facebook
  • X logo X
  • LinkedIn logo LinkedIn
  • Forward logo Forward
  • Home
  • Courses
  • About Us
    • Accreditation
    • Annual Report
    • Awards and Publications
    • Mission Statements
    • Our Team
    • Advisory Board
    • Privacy Policy
    • CE Champion Award
    • Healthcare CE Professionals Day
  • Contact us
  • Help
  • QI Hub
  • SHIELD

You are here

Home

Sessions

Session Datesort descending
Relapsed FL and Novel Agents for Treatment (Part 1) 08/09/2021 - 5:11pm EDT
First-Line Treatment of Metastatic Triple Negative Breast Cancer 08/23/2021 - 5:11pm EDT
HIV-Associated Hodgkin Lymphoma 08/30/2021 - 5:11pm EDT
Management of Hereditary Breast Cancer 09/13/2021 - 5:11pm EDT
Ph+ B-ALL in Adults 09/20/2021 - 5:11pm EDT
Cardiotoxicity in Multiple Myeloma Treatment 09/27/2021 - 5:11pm EDT
Suspected Refractory DLBCL in Medically Fit Patients 10/04/2021 - 5:11pm EDT
Neoadjuvant therapy for early stage breast cancer 10/18/2021 - 5:11pm EDT
Immunotherapy in the Treatment of Advanced Driver Negative NSCLC 10/25/2021 - 5:11pm EDT
First Line Treatment for Early Stage Unfavorable Hodgkin’s Lymphoma 11/01/2021 - 5:11pm EDT

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • next ›
  • last »

Features

  • Home
  • Sessions

© 2026 BOSTON UNIVERSITY ALL RIGHTS RESERVED.
PRIVACY POLICY · ABOUT Boston University Chobanian & Avedisian School of Medicine, Barry M. Manuel Center for Continuing Education

LinkedIn · X 
[email protected] · 617.358.5005

Powered by the EthosCE Learning Management System, a continuing education LMS.
    • Home
    • Courses
    • About Us
      • Accreditation
      • Annual Report
      • Awards and Publications
      • Mission Statements
      • Our Team
      • Advisory Board
      • Privacy Policy
      • CE Champion Award
      • Healthcare CE Professionals Day
    • Contact us
    • Help
    • QI Hub
    • SHIELD